We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.50 | 0.28% | 1,594.50 | 1,594.00 | 1,594.50 | 1,595.00 | 1,584.50 | 1,593.00 | 281,972 | 09:04:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.28 | 65.46B |
TIDMGSK
RNS Number : 7833U
GlaxoSmithKline PLC
16 July 2018
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Ms E Walmsley === ======================== ============================================ b) Position/status Chief Executive Officer === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 12 July 2018. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP15.7091 1450.373 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2018-07-12 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr R G Connor === ======================== ============================================ b) Position/status President, Global Manufacturing & Supply === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 12 July 2018. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP15.7091 39.972 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2018-07-12 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr L Debruyne === ======================== ============================================ b) Position/status President, Global Vaccines === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 12 July 2018. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP15.7091 1046.463 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2018-07-12 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr S Dingemans === ======================== ============================================ b) Position/status Chief Financial Officer === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 12 July 2018. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP15.7091 992.245 ---------- === ======================== ============================================
d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2018-07-12 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr N Hirons === ======================== ============================================ b) Position/status SVP, Global Ethics and Compliance === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 12 July 2018. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP15.7091 292.397 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2018-07-12 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr D S Redfern === ======================== ============================================ b) Position/status Chief Strategy Officer === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 12 July 2018. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP15.7091 1837.506 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2018-07-12 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Ms C Thomas === ======================== ============================================ b) Position/status SVP, Human Resources === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 12 July 2018. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP15.7091 1165.071 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2018-07-12 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mr P C Thomson === ======================== ============================================ b) Position/status President, Global Affairs === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 12 July 2018. === ======================== ============================================
c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP15.7091 971.581 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2018-07-12 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================ 1. Details of PDMR/person closely associated with them ('PCA') ====================================================================== a) Name Mrs K Thomson === ======================== ============================================ b) Position/status PCA of Mr P C Thomson (President, Global Affairs) === ======================== ============================================ c) Initial notification/ Initial notification amendment === ======================== ============================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================== a) Name GlaxoSmithKline plc === ======================== ============================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================ b) Nature of the Acquisition of Ordinary Shares following transaction the re-investment of dividends paid to shareholders on 12 July 2018. === ======================== ============================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- GBP15.7091 120.372 ---------- === ======================== ============================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ============================================ e) Date of the transaction 2018-07-12 === ======================== ============================================ f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHXQLFFVDFZBBK
(END) Dow Jones Newswires
July 16, 2018 09:51 ET (13:51 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions